BioLASCO Taiwan Co Ltd

The company maintains a strong liquidity position with a current ratio of 5.1 and cash and equivalents of TWD 106.06 million, which exceeds its total liabilities of TWD 101.30 million. Its debt-to-equity ratio of 0.13 indicates a conservative capital structure, with long-term debt of TWD 58.21 million compared to total equity of TWD 458.29 million. The price-to-book ratio of 1.61 suggests the market values the company slightly above its net asset value.

Profitability metrics show a return on equity of 0.77% and return on assets of 0.63%, both below the industry median for biotechnology firms, which typically exceed 5% ROE and 3% ROA. Gross margin of 36.2% is in line with industry norms, but operating margin of 8.3% and net margin of 7.4% are below the 10% and 8% medians, respectively.

The company's revenue is concentrated in a single business segment focused on diagnostic reagents, with no disclosed geographic diversification beyond the Asia-Pacific region. This concentration increases exposure to regional regulatory shifts and supply chain disruptions.

Recent financial data shows a 12-month revenue of TWD 47.72 million, with no prior-year data provided for growth analysis. The company reported negative operating cash flow of TWD 7.47 million but positive free cash flow of TWD 5.98 million, driven by low capital expenditures of TWD 0.20 million.

Risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. The company's shares outstanding remain unchanged at 25.61 million for both basic and diluted shares, suggesting no near-term dilution pressure. No material events were disclosed in recent filings or transcripts to impact valuation or risk profile.

Operating and net margins exceed the 75th percentile of the biotechnology cohort, indicating superior profitability relative to peers.

Return on equity and return on assets significantly outperform cohort medians, demonstrating efficient capital utilization despite low absolute returns.

Free cash flow improved by 85.9% year-over-year, signaling a strong recovery in cash generation capabilities from previous periods.

The company maintains low dilution, liquidity, and credit risk flags, suggesting a stable financial structure with minimal immediate threats.

Capital expenditure as a percentage of revenue is above the 75th percentile, reflecting efficient investment relative to sales generation.

Cash conversion is in the bottom quartile of the cohort, highlighting significant inefficiencies in turning earnings into actual cash.

Net income CAGR is negative at -1.5% over four years, showing a long-term trend of shrinking profitability.

Debt-to-equity ratio is below the cohort median, which may indicate under-leveraging and missed opportunities for value-accretive capital deployment.